BioStar
This article was originally published in The Gray Sheet
Executive Summary
Receives FDA market go-ahead for the FLU OIA rapid test for influenza, the firm reports Dec. 2. The test, which employs the company's proprietary optical immunoassay technology and can be used by physicians in their offices, is the only test on the market that can detect both influenza A and B within 20 minutes, according to BioStar. The recently acquired subsidiary of Thermo BioAnalysis ("The Gray Sheet" Sept. 7, p. 14) will share profits from the test with Biota Holdings Limited of Australia, which collaborated on the product's development